Adenosine Receptor Antagonist Combination Therapy for Prostate Cancer
(ARC-6 Trial)
Recruiting in Palo Alto (17 mi)
+22 other locations
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Arcus Biosciences, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study is evaluating whether a drug may help treat prostate cancer.
Research Team
MD
Medical Director
Principal Investigator
Arcus Biosciences
Eligibility Criteria
Men over 18 with advanced prostate cancer that's resistant to hormone therapy and has spread, who haven't had certain recent treatments or infections, can join. They need a life expectancy of at least 3 months, no severe heart issues or lung conditions like fibrosis, and must not have brain metastases or another cancer within the last two years.Inclusion Criteria
Life expectancy of at least 3 months
My prostate cancer has spread and does not respond to hormone therapy.
I am a man aged 18 or older.
See 8 more
Exclusion Criteria
I have been treated with immune checkpoint inhibitors before.
Corrected QT interval (QTc) ≥480 msec using Fredericia's QT correction formula (based on an average of triplicate recordings)
I cannot swallow pills.
See 15 more
Treatment Details
Interventions
- Etrumadenant (Adenosine Receptor Antagonist)
Trial OverviewThe trial is testing combinations of drugs including Docetaxel, SG (an unspecified agent), Etrumadenant, Zimberelimab, Quemliclustat, and Enzalutamide for their effectiveness in treating advanced prostate cancer. It's an early-phase trial to see how well these drugs work together.
Participant Groups
10Treatment groups
Experimental Treatment
Active Control
Group I: Stage 2: Etrumadenant + zimberelimab + quemliclustatExperimental Treatment3 Interventions
Participants will receive oral etrumadenant in combination with IV zimberelimab and IV quemliclustat
Group II: Stage 2: Etrumadenant + quemliclustatExperimental Treatment2 Interventions
Participants will receive oral etrumadenant in combination with IV quemliclustat
Group III: Stage 1: Etrumadenant + zimberelimab PK Sub-StudyExperimental Treatment2 Interventions
Participants will receive oral etrumadenant in combination with IV zimberelimab
Group IV: Stage 1 and 2: Etrumadenant + zimberelimab + enzalutamideExperimental Treatment3 Interventions
Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab and standard oral enzalutamide
Group V: Stage 1 and 2: Etrumadenant + zimberelimab + docetaxelExperimental Treatment3 Interventions
Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel
Group VI: Stage 1 and 2: Etrumadenant + zimberelimabExperimental Treatment2 Interventions
Oral etrumadenant in combination IV zimberelimab
Group VII: Stage 1 and 2: Etrumadenant + Zimberelimab + SGExperimental Treatment3 Interventions
Participants will receive oral etrumadenant in combination with IV zimberelimab and SG.
Group VIII: Stage 1 and 2: Etrumadenant + SGExperimental Treatment2 Interventions
Participants will receive oral etrumadenant in combination with IV SG.
Group IX: Stage 2: docetaxelActive Control1 Intervention
Participants will receive standard dose of IV docetaxel
Group X: Stage 2: enzalutamideActive Control1 Intervention
Participants will receive standard oral enzalutamide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arcus Biosciences, Inc.
Lead Sponsor
Trials
44
Recruited
7,500+
Gilead Sciences
Industry Sponsor
Trials
1,150
Recruited
878,000+
Daniel O'Day
Gilead Sciences
Chief Executive Officer since 2019
MBA from Columbia University
Dietmar Berger
Gilead Sciences
Chief Medical Officer
MD and PhD from Albert-Ludwigs University School of Medicine